ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The development of Imatinib mesylate (IM), which targets the oncogenic BCR-ABL fusion protein, has greatly improved the outcome of Chronic Myeloid Leukemia (CML) patients.